Immanuel Klinik Märkische Schweiz

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vsTamoxifen in Premenopausal Women with Early Breast Cancer Indirekter Behandlungsvergleich von Ribociclib kombiniert mit nichtsteroidalen Aromatasehemmern und ovarieller Funktionsunterdrückung mit Tamoxifen bei prämenopausalen Frauen mit Brustkrebs im Frühstadium (2025) Lüftner D, Banys-Paluchowski M, Hartkopf AD, Hörner M, Janni W, Langanke D, Müller V, et al. Journal article ABC7 Consensus: Assessment by a German Group of Experts (2024) Ditsch N, Untch M, Fasching P, Busch S, Ettl J, Haidinger R, Jackisch C, et al. Journal article Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer (2024) Würstlein R, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Schütz F, Fasching P, et al. Journal article Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective (2024) Krug D, Banys-Paluchowski M, Brucker SY, Denkert C, Ditsch N, Fasching P, Haidinger R, et al. Journal article, Review article Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy (2023) Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, et al. Journal article, Review article PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant (2023) Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, et al. Journal article Treatment of Early Breast Cancer The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations Behandlung des frühen Mammakarzinoms 18. Internationaler St.-Gallen-Konsens vor dem Hintergrund der aktuellen deutschen Therapieempfehlungen diskutiert (2023) Untch M, Banys-Paluchowski M, Brucker SY, Budach W, Denkert C, Ditsch N, Fasching P, et al. Journal article Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer (2023) Lüftner D, Lux MP, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, et al. Journal article, Review article